Mutational Heterogeneity in Human Cancers: Origin and Consequences

Annual Review of Pathology: Mechanisms of Disease

Volumn 5, Issue , 2010, Pages 51-75

  Salk, Jesse J ^a   Fox, Edward J ^a   Loeb, Lawrence A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cancer genome; DNA sequencing; Evolution

Indexed keywords

APC PROTEIN; CELL NUCLEUS DNA; IMATINIB; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; UNCLASSIFIED DRUG; XRCC1 PROTEIN; DNA;

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RESEARCH; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA SEQUENCE; DNA STRUCTURE; DNA SYNTHESIS; EPIGENETICS; EVOLUTION; EXCISION REPAIR; FAMILIAL CANCER; GENE DELETION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOME; GLIOBLASTOMA; HUMAN; HUMAN GENOME; INDEL MUTATION; MISMATCH REPAIR; MUTATION RATE; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GROWTH; XERODERMA PIGMENTOSUM; GENETICS; HUMAN GENOME PROJECT; MOLECULAR EVOLUTION; MUTATION; NEOPLASM;

DNA, NEOPLASM; EVOLUTION, MOLECULAR; HUMAN GENOME PROJECT; HUMANS; MUTATION; NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 75749100093     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-121808-102113     Document Type: Review

References (129)

1. Boveri T. 1902. ÜbermehrpoligeMitosen alsMittel zur Analyze des Zellkerns. Verh. Dtsch. Zool. Ges. Würzburg 35:67-90
2. Cleaver JE. 1968. Defective repair replication of DNA in xeroderma pigementosum. Nature 218:652-656
3. Kallioniemi A, Kallioniemi O-P, Piper J, Tanner M, Stokke T, et al. 1994. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc. Natl. Acad. Sci. USA 91:2156-2160
4. Riopel MA, Spellerberg A, Griffin CA, Perlman EJ. 1998. Genetic analysis of ovarian germ cell tumors by comparative genomic hybridization. Cancer Res. 58:3105-3110
5. El-Rifai W, Sarlomo-Rikala M, Knuutila S, Miettinen M. 1998. DNA copy number changes in development and progression in leiomyosarcomas of soft tissues. Am. J. Pathol. 153:985-990 (Pubitemid 28419051)
6. Kerangueven F, Noguchi T, Coulier F, Allione F,Wargniez V, et al. 1997. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carnomas. Cancer Res. 57:5469-5474
7. Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmuller G. 1999. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl. Acad. Sci. USA 96:4494-4499
8. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, et al. 1988. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319:525-532
9. Albertini RJ, Nicklas JA, O'Neill JP, Robison SH. 1990. In vivo somatic mutations in humans: measurement and analysis. Annu. Rev. Genet. 24:305-326
10. Bielas JH, Heddle JA. 2003. Elevated mutagenesis and decreasedDNArepair at a transgene are associated with proliferation but not apoptosis in p53-deficient cells. Proc. Natl. Acad. Sci. USA 100:12853-12858
11. Chu EHY, Boehnke M, Hanash SM, Kuick RD, Lamb BJ, et al. 1988. Estimation of mutation rates based on the analysis of polypeptide constituents of cultured human lymphoblastoid cells. Genetics 119:693-703
12. DeMars R, Held KR. 1972. The spontaneous azaguanine-resistant mutants of diploid human fibroblasts. Humangenetik 16:87-110
13. Cervantes RB, Stringer JR, Shao C,Tischfield JA, Stambrook PJ. 2002. Embryonic stem cells and somatic cells differ in mutation frequency and type. Proc. Natl. Acad. Sci. USA 99:3586-3590
14. Jackson AL, Loeb LA. 1998. The mutation rate and cancer. Genetics 148:1483-1490
15. Ferrin LJ, Beckman RA, Loeb LA, Mildvan AS. 1986. Kinetic and magnetic resonance studies of the interaction of Mn2+, substrates and templates with DNA polymerases. In Manganese in Metabolism and Enzyme Function, ed. VL Schramm, FCWedler, pp. 259-273 New York: Academic
16. Petruska J, Sowers LC, Goodman MF. 1986. Comparison of nucleotide interactions in water, proteins and vacuum: model for DNA polymerase fidelity. Proc. Natl. Acad. Sci. USA 83:1559-1562
17. Loeb LA, Monnat R. 2008. DNA polymerases and human disease. Nat. Rev. Genet. 9:594-604
18. Uyemura D, Lehman IR. 1976. Biochemical characterization of mutant forms of DNA polymerase I from Escherichia coli. I. The polA12 mutation. J. Biol. Chem. 251:4078-4084
19. Modrich P, Lahue R. 1996. Mismatch repair in replication fidelity, genetic recombination and cancer biology. Annu. Rev. Biochem. 65:101-133
20. Kunkel TA, Schaaper RM, Loeb LA. 1983. Depurination-induced infidelity of DNA synthesis with purified DNA replication proteins in vitro. Biochemistry 22:2378-2384
21. Kiel MJ, He S, Ashkenazi R, Gentry SN, Teta M, et al. 2007. Haematopoietic stem cells do not asymmetrically segregate chromosomes or retain BrdU. Nature 449:238-242
22. Nishimura S. 2006. 8-hydroxyguanine: from its discovery in 1983 to the present status. Proc. Jpn. Acad. 82:127-141
23. Floyd RA. 1995. Measurement of oxidative stress in vivo. In The Oxygen Paradox, ed. KJA Davies, F Ursini, pp. 89-103. Padova, Italy: CLEUP Univ. Press
24. Lindahl T,Wood RD. 1999. Quality control by DNA repair. Science 286:1897-1905
25. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, et al. 1999. Evolution of neoplastic cell lineages in Barrett esophagus. Nat. Genet. 22:106-109
26. Bronner MP, O'Sullivan JN, Rabinovitch PS, Crispin DA, Chen L, et al. 2008. Genomic biomarkers to improve ulcerative colitis neoplasia surveillance. Am. J. Pathol. 173:1853-1860
27. Baik SC, Youn HS, Chung MH, Lee WK, Cho MJ, et al. 1996. Increased oxidative DNA damage in Heliocobacter pylori-infected human gastric mucosa. Cancer Res. 56:1279-1282
28. Fausto N,WebberEM.1993. Mechanisms of growth regulation in liver regeneration and hepatic carcinogenesis. In Progress in Liver Diseases, ed. JL Boyer, RK Okner, 11:115-137 Philadelphia:W.B. Saunders
29. Feig DI, Loeb LA. 1994. Oxygen radical induced mutagenesis is DNA polymerase specific. J. Mol. Biol. 235:33-41
30. Ames BN, Durston WE, Yamasaki E, Lee FD. 1973. Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl. Acad. Sci. USA 70:2281-2285
31. Auerbach C, Robson JM. 1946. Chemical production of mutations. Nature 154:302
32. Loeb L, Harris CC. 2008. Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res. 68:6863-6872
33. Hecht SS. 1999. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 91:1194-1210
34. Wynder EL, Graham EA. 1950. Tobacco smoking as a possible etiologic factor in bronchogenic carcinoma. JAMA 143:329-336
35. Loeb LA, Ernster VL, Warner KE, Abbotts J, Laszlo J. 1984. Smoking and lung cancer: an overview. Cancer Res. 44:5940-5958
36. Friedberg EC, Aguilera A, Gellert M, Hanawalt PC, Hays JB, et al. 2006. DNA repair: from molecular mechanism to human disease. DNA Repair 5:986-996
37. Hoeijmakers JH. 2001. Genome maintenance mechanisms for preventing cancer. Nature 411:366-374
38. Harris CC. 1993. p53: at the crossroads of molecular carcinogenesis and cancer risk assessment. Science 262:1980-1981
39. Kolodner RD, Marsischky GT. 1999. EukaryoticDNAmismatch repair. Curr. Opin. Genet. Dev. 9:89-96
40. Al-Tassan N, Chmiel NH,Maynard J, Fleming N, Livingston AL, et al. 2002. Inherited variants ofMYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat. Genet. 30:227-232
41. King MC, Marks JH, Mandell JB. 2003. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646
42. Riballo E, Critchlow SE, Teo SH, Doherty AJ, Priestley A, et al. 1999. Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr. Biol. 9:699-702
43. Masutani C, Araki M, Yamada A, Kusumoto R, Nogimori T, et al. 1999. Xeroderma pigmentosum variant (XP-V) correcting protein from HeLa cells has a thymine dimer bypassDNApolymerase activity. EMBO J. 18:3491-3501
44. Ellis NA, Groden J, Ye T-Z, Straughen J, Lennon DJ, et al. 1995. The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 83:655-666
45. Kamath-Loeb AS, Lan L, Nakajima S, Yasui A, Loeb LA. 2007. TheWerner syndrome protein interacts functionally with translesion DNA polymerases. Proc. Natl. Acad. Sci. USA 104:10394-10399
46. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331
47. Goode EL, Ulrich CM, Potter JD. 2002. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomark. Prev. 11:1513-1530
48. Webber EM, Wu JC, Wang L, Merlino G, Fausto N. 1994. Overexpression of transforming growth factor-? causes liver enlargement and increased hepatocyte proliferation in transgenic mice. Am. J. Pathol. 145:398-408
49. Hecker E. 1967. Phorbol esters from croton oil. Chemical nature and biological activities. Naturwissenschaften 54:282-284
50. Rous P. 1911. Transmission of a malignant new growth by means of a cell-free filtrate. JAMA 56:198
51. Varmus HE, Shank PR, Hughes SE, Kung HJ,Heasley S, et al. 1979. Synthesis, structure, and integration of the DNA of RNA tumor viruses. Cold Spring Harb. Symp. Quant. Biol. 43(Part 2):851-864
52. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70
53. Reya T, Morrison SJ, Clarke MF,Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature 414:105-11
54. Pepper JW, Sprouffske K, Maley CC. 2007. Animal cell differentiation patterns suppress somatic evolution. PLoS Comput. Biol. 3(12):e50
55. Humphries A,Wright NA. 2008. Colonic crypt organization and tumorigenesis. Nat. Rev. Cancer 8:415-424
56. Cairns J. 2006. Cancer and the immortal strand hypothesis. Genetics 174:1069-1072
57. Prindull GA, Fibach E. 2007. Are postnatal hemangioblasts generated by dedifferentiation from committed hematopoietic stem cells? Exp. Hematol. 35:691-701
58. Nowell PC. 1976. The clonal evolution of tumor cell populations. Science 194:23-28
59. Merlo LM, Pepper JW, Reid BJ, Maley CC. 2006. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6:924-935
60. Cairns J. 1975. Mutation selection and the natural history of cancer. Nature 255:197-200
61. Armitage P, Doll R. 1954. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer 8:1-12
62. Knudson AG. 1996. Hereditary cancer: two hits revisited. J. Cancer Res. Clin. Oncol. 122:135-140
63. Renan MJ. 1993. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol. Carcinog. 7:139-146
64. Rangarajan A, Hong SJ, Gifford A,Weinberg RA. 2004. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 6:171-183
65. Mahale AM, Khan ZA, Igarashi M, Nanjangud GJ, Qiao RF, et al. 2008. Clonal selection in malignant transformation of human fibroblasts transduced with defined cellular oncogenes. Cancer Res 68:1417-1426
66. BodmerW.2008. Genetic instability is not a requirement for tumor development. Cancer Res. 68:3558-3561
67. Mahale AM, Khan ZA, Igarashi M, Nanjangud GJ, Qiao RF, et al. 2008. Clonal selection in malignant transformation of human fibroblasts transduced with defined cellular oncogenes. Cancer Res. 68:1417-1426
68. BodmerW.2008. Genetic instability is not a requirement for tumor development. Cancer Res. 68:3558-3561
69. Loeb LA, Bielas JH, Beckman RA. 2008. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 68:3551-3557
70. Lengauer C, Kinzler KW,Vogelstein B. 1998. Genetic instabilities in human cancers. Nature 396:643-649
71. Moolgavkar SH, Luebeck EG. 2003. Multistage carcinogenesis and the incidence of human cancer. Genes Chromosomes Cancer 38:302-306
72. Loeb LA, Springgate CF, Battula N. 1974. Errors in DNA replication as a basis of malignant change. Cancer Res. 34:2311-2321
73. Loeb LA, Loeb KR, Anderson JP. 2003. Multiple mutations and cancer. Proc. Natl. Acad. Sci. USA 100:776-781
74. Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, et al. 2007. Genetic progression and the waiting time to cancer. PLoS Comput. Biol. 3:e225
75. Tomlinson IP, Novelli MR, Bodmer WF. 1996. The mutation rate and cancer. Proc. Natl. Acad. Sci. USA 93:14800-14803
76. Beckman RA, Loeb LA. 2006. Efficiency of carcinogenesis with and without a mutator mutation. Proc. Natl. Acad. Sci. USA 103:14140-15
77. Beckman RA. 2009. Mutator mutations enhance tumorigenic efficiency across fitness landscapes. PLoS One 4:e5860
78. Beckman RA, Loeb LA. 2005. Negative clonal selection in tumor evolution. Genetics 171:2123-2131
79. Robins H, Alexe G, Harris SL, Levine AJ. 2005. The first twenty-five years of p53 research. InTwenty-Five Years of p53 Research, ed. P Hainaut, KGWiman, pp. 1-26. Dordrecht: Springer
80. Wells RD, Sinden RR. 1993. Defined ordered sequence DNA, DNA structure, and DNA-directed mutation. In Genome Analysis, Genome Rearrangement and Stability, 7:107-138 Plainview,NY: Cold Spring Harb. Lab. Press
81. Farber RA, Petes TD, Dominska M, Hudgens SS, Liskay RM. 1994. Instability of simple sequence repeats in a mammalian cell line. Hum. Mol. Genet. 3:253-256
82. Hanawalt PC, Spivak G. 2008.Transcription-coupledDNArepair: two decades of progress and surprises. Nat. Rev. Mol. Cell Biol. 9:958-970
83. Stamatoyannopoulos JA, Adzhubei I, Thurman RE, Kryukov GV, Mirkin SM, Sunyaev SR. 2009.Human mutation rate associated with DNA replication timing. Nat. Genet. 41:393-395
84. Balaban GB, Herlyn M, Clark WH Jr, Nowell PC. 1986. Karyotypic evolution in human malignant melanoma. Cancer Genet. Cytogenet. 19:113-122
85. Smith G, Carey FA, Beattie J, Wilkie MJV, Lightfoot TJ, et al. 2002. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc. Natl. Acad. Sci. USA 99:9433-9438
86. Ley TJ, Mardis E, Ding L, Fulton B, McLellan M, et al. 2008.DNAsequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456:66-72
87. Druker BJ. 2004. Imatinib: paradigm or anomaly? Cell Cycle 3:833-835
88. Wang TL, Rago C, Silliman N, Ptak J, Markowitz S, et al. 2002. Prevalence of somatic alterations in the colorectal cancer cell genome. Proc. Natl. Acad. Sci. USA 99:3076-3080
89. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, et al. 2004. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304:1164-1166
90. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, et al. 2003. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300:949
91. Sjöblom T, Jones S,Wood LD, Parsons DW, Lin J, et al. 2006. The concensus coding sequences of human breast and colorectal cancers. Science 314:268-274
92. Wood LD, ParsonsDW, Jones S, Lin J, SjöblomT, et al. 2007.The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113
93. Kudla G, Murray AW, Tollervey D, Plotkin JB. 2009. Coding-sequence determinants of gene expression in Escherichia coli. Science 324:255-258
94. Getz G, Hofling H, Mesirov JP, Golub TR, Meyerson M, et al. 2007. Comment on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers." Science 317:1500
95. Rubin AF, Green P. 2007. Comment on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers." Science 317:1500
96. Forrest WF, Cavet G. 2007. Comment on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers." Science 317:1500
97. Parmigiani G, Lin J, Boca S, Sjöblom T, Jones S, et al. 2007. Response to comments on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers." Science 317:1500
98. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. 2007. Patterns of somatic mutation in human cancer genomes. Nature 446:153-158
99. Stephens P, Edkins S, Davies H, Greenman C, Cox C, et al. 2005. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat. Genet. 37:590-592
100. Davies H, Hunter C, Smith R, Stephens P, Greenman C, et al. 2005. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 65:7591-7595
101. Bignell G, Smith R, Hunter C, Stephens P, Davies H, et al. 2006. Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Genes Chromosomes Cancer 45:42-46
102. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, et al. 2008. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl. Acad. Sci. USA 105:4283-4288
103. Jones S, Zhang X, Parsons D, Lin J, Leary R, et al. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806
104. Prehn RT, Main JM. 1957. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18:769-778
105. Segal N, Parsons D, Peggs K, Velculescu V, Kinzler K, et al. 2008. Epitope landscape in breast and colorectal cancer. Cancer Res. 68:889-892
106. Leary RJ, Lin JC, Cummins J, Boca S,Wood LD, et al. 2008. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc. Natl. Acad. Sci. USA 105:16224-16229
107. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
108. Cancer Genome Atlas Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068
109. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. 2008. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116:597-602
110. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. 2009. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360:765-773
111. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, et al. 2009. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1?. Science 324:261-361
112. Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. 2007. Characterizing the cancer genome in lung adenocarcinoma. Nature 450:893-898
113. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075
114. Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, et al. 2008. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 111:4797-4808
115. Loriaux MM, Levine RL, Tyner JW, Frohling S, Scholl C, et al. 2008. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 111:4788-4796
116. Campbell PJ, Stephens PJ, Pleasance ED, O'Meara S, Li H, et al. 2008. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat. Genet. 40:722-729
117. Lai LA, Paulson TG, Li X, Sanchez CA, Maley C, et al. 2007. Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer 46:532-542
118. Shames DS, Girard L, Gao B, Sato M, Lewis CM, et al. 2006. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 3:e486
119. Stoecklein NH, Hosch SB, Bezler M, Stern F, Hartmann CH, et al. 2008. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 13:441-453
120. Shames DS, Girard L, Gao B, Sato M, Lewis CM, et al. 2006. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 3:e486
121. Stoecklein NH, Hosch SB, Bezler M, Stern F, Hartmann CH, et al. 2008. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 13:441-453
122. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, et al. 2005. Dynamics of chronic myeloid leukaemia. Nature 435:1267-1270
123. Radich JP, Dai H, Mao M, Oehler V, Schelter J, et al. 2006. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA. 103:2794-2799
124. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, et al. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354:2531-2541 (Pubitemid 43882349)
125. Golub TR. 2003. Mining the genome for combination therapies. Nat. Med. 9:510-511
126. Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, et al. 2008. Subclonal phylogenetic structures in cancer revealed by ultradeep sequencing. Proc. Natl. Acad. Sci. USA 105:13081-13086
127. Bielas J, Loeb LA. 2005. Quantification of random genomic mutations. Nat. Methods 2:285-290
128. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. 2006. Human cancers express a mutator phenotype. Proc. Natl. Acad. Sci. USA 103:18238-18242
129. Zheng L, Dai H, Zhou M, Li M, Singh P, et al. 2007. Fen1 mutations result in autoimmunity, chronic inflammation and cancers. Nat. Med. 13:812-819